Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650749 · ClinicalTrials.gov registry record · Phase 1
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
A Phase 1 study of Retinoblastoma and High-risk Neuroblastoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05650749: Recruiting Phase 1 study of Retinoblastoma and High-risk Neuroblastoma, sponsored by Stephan Grupp MD PhD.
NCT05650749 is a Phase 1 study of Retinoblastoma and High-risk Neuroblastoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 45 participants, below the 590-participant average among 15 other Retinoblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05650749, a Phase 1 study of Retinoblastoma and High-risk Neuroblastoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
Conditions Studied
Interventions
- BIOLOGICAL GPC2 CAR T cells
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2030-01-30 |
| Phase | Phase 1 |
What NCT05650749 shows while recruiting
NCT05650749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 590-participant average among 15 other Retinoblastoma trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Retinoblastoma appearing as the primary indexed condition, and to 1 intervention - of which GPC2 CAR T cells is the first listed.
NCT05650749 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05650749 about?
NCT05650749 is a clinical study titled "GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma". This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
What is the current status of trial NCT05650749?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-05-23. Estimated completion is 2030-01-30.
What conditions does trial NCT05650749 study?
This clinical trial studies the following conditions: Retinoblastoma, High-risk Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Metastatic Retinoblastoma.
What interventions are being tested in trial NCT05650749?
The interventions under investigation include: GPC2 CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05650749?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650749 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05650749's enrollment target sits among peer trials
45 10th of 15 higher than 6 of 15 other Retinoblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinoblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
COMPLETED · Phase 1
-
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
COMPLETED · Phase 1
-
RB Liquid Biopsy Biorepository
RECRUITING
-
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI